by Alex Bajjon | Oct 1, 2016 | Briefings, UK
Arrow Declarations The term “Arrow Declaration” refers to a declaration that the subject-matter of an invention is not patentable. The term stems from the case Arrow v Merck [2007] EWHC 1900 (Pat) where such a declaration was first issued. Unlike...
by David Eyre | Mar 1, 2016 | UK
In a recent article on this website we examined the case of Actavis vs Lilly and the “plausibility” test for sufficiency of disclosure used in that case. We noted that that this was a departure from the test for sufficiency that has been used previously and that this...
by Juliette Boynton | Jan 1, 2016 | Briefings, UK
In a second medical use patent to the “Use of tomoxetine for the manufacture of a medicament for treating attention-deficit/hyperactivity disorder”, EP(UK) 0721777, no data was provided to support the claimed invention. Actavis sought to revoke the patent on the...
by David Eyre | Jan 1, 2016 | US & International
The origin of the PTE system flows from a desire to compensate those who have invested time and resources in making or finding new medical products for the additional burden of gaining regulatory approval for that product. Thus, originally, the PTE provisions were...
by | Oct 1, 2015 | Briefings, UK
Warner-Lambert is proprietor of a European patent (EP 0641330) which claims the compound pregabalin (via compound per se claims). The Supplementary Protection Certificate (SPC) was (surprisingly) allowed to lapse in October 2013 for non-payment of fees resulting in...
Recent Comments